First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION study

Park K.CHONG-JEN YUKim S.-W.Lin M.-C.Sriuranpong V.Tsai C.-M.Lee J.-S.Kang J.-H.Chan K.C.A.Perez-Moreno P.Button P.Ahn M.-J.Mok T.2022-06-272022-06-2720162374-2437https://www.scopus.com/inward/record.uri?eid=2-s2.0-84979503381&doi=10.1001%2fjamaoncol.2015.4921&partnerID=40&md5=af0a2d80f86a0a3a2129c94159eb7087https://scholars.lib.ntu.edu.tw/handle/123456789/614147[SDGs]SDG3First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION studyjournal article10.1001/jamaoncol.2015.4921267204232-s2.0-84979503381